INBX

Inhibrx Biosciences, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $97.93
52-Week Range: $28.16 – $155.29
Market Cap: $1.43B
P/E (TTM): —
EPS (TTM): -8.88
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -1773.60%
Return on Assets: -43.61%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 5.07
Debt/Equity: —
Total Debt: $181.63M
Free Cash Flow: $-85.10M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.48B

INBX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.30M	$1.80M	$200.00K	$1.30M
Research & Development	$101.60M	$191.64M	$203.74M	$113.03M
Selling, General & Admin	$15.04M	$29.38M	$127.50M	$23.12M
Operating Expenses	$116.62M	$221.02M	$331.65M	$136.32M
Operating Income	-$115.32M	-$219.22M	-$331.45M	-$135.03M
EBITDA	-$114.10M	-$206.69M	$1.70B	-$125.37M
Pretax Income	-$115.32M	-$239.72M	$1.69B	-$140.05M
Income Tax	$3.00K	$3.00K	$2.00K	$2.00K
Net Income	-$115.33M	-$241.36M	$1.69B	-$140.06M
Diluted EPS	-8.10	-16.95	112.62	-9.04
Diluted Shares	14.24M	14.24M	14.98M	15.49M

INBX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	—	$277.92M	$152.60M	$124.22M
Receivables	$257.00K	$778.00K	$420.00K	$177.00K
Current Assets	$6.26M	$295.36M	$160.40M	$132.83M
Total Assets	$16.64M	$307.89M	$180.77M	$146.48M
Current Liabilities	$20.77M	$56.31M	$40.73M	$33.80M
Long-Term Debt	—	$206.97M	—	$100.56M
Total Debt	$5.03M	$210.14M	$8.05M	$107.01M
Total Liabilities	$23.95M	$264.39M	$47.18M	$138.49M
Retained Earnings	—	-$613.73M	-$106.13M	-$246.19M
Shareholders' Equity	-$7.30M	$43.50M	$133.58M	$7.99M
Working Capital	-$14.51M	$239.05M	$119.67M	$99.03M

INBX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$90.81M	-$193.31M	-$194.41M	-$129.79M
Capital Expenditure	-$686.00K	-$4.59M	-$2.60M	-$31.00K
Free Cash Flow	-$91.50M	-$197.90M	-$197.01M	-$129.82M
Depreciation & Amortisation	$1.23M	$1.19M	$2.29M	$2.48M
Stock-Based Compensation	$17.79M	$24.85M	$58.52M	$11.14M
Investing Cash Flow	-$686.00K	-$4.59M	-$2.60M	-$28.00K
Financing Cash Flow	$91.50M	$201.96M	$71.68M	$101.45M
Net Change in Cash	—	$4.06M	-$125.33M	-$28.38M

INBX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$1.30M	$0.00	$0.00	$0.00	$0.00
Research & Development	$36.88M	$22.27M	$28.54M	$25.35M	$25.22M	$23.90M
Selling, General & Admin	$6.02M	$6.42M	$5.28M	$5.39M	$5.71M	$8.25M
Operating Expenses	$42.90M	$28.69M	$33.81M	$30.92M	$30.93M	$32.15M
Operating Income	-$42.90M	-$27.39M	-$33.81M	-$30.92M	-$30.93M	-$32.15M
EBITDA	-$39.95M	-$24.85M	-$31.49M	-$29.09M	-$29.39M	-$30.43M
Pretax Income	-$43.31M	-$28.65M	-$35.26M	-$32.83M	-$33.44M	-$36.65M
Income Tax	$0.00	$2.00K	$0.00	$0.00	$0.00	$3.00K
Net Income	-$43.31M	-$28.65M	-$35.26M	-$32.83M	-$33.44M	-$36.65M
Diluted EPS	-2.80	-1.85	-2.28	-2.11	-2.15	-2.34
Diluted Shares	15.47M	15.47M	15.48M	15.53M	15.59M	15.67M

INBX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$216.52M	$186.57M	$153.09M	$124.22M	$161.66M	$133.34M
Receivables	$214.00K	$967.00K	$837.00K	$177.00K	$186.00K	$132.00K
Current Assets	$223.39M	$193.96M	$161.42M	$132.83M	$171.34M	$142.21M
Total Assets	$242.64M	$212.12M	$177.47M	$146.48M	$183.97M	$154.22M
Current Liabilities	$43.64M	$38.94M	$35.98M	$33.80M	$26.51M	$28.06M
Long-Term Debt	$98.65M	$99.28M	$99.92M	$100.56M	$174.99M	$176.28M
Total Debt	$106.53M	$106.79M	$106.91M	$107.01M	$180.90M	$181.63M
Total Liabilities	$148.20M	$143.56M	$140.64M	$138.49M	$205.00M	$207.20M
Retained Earnings	-$149.44M	-$178.10M	-$213.35M	-$246.19M	-$279.63M	-$316.28M
Shareholders' Equity	$94.44M	$68.56M	$36.83M	$7.99M	-$21.04M	-$52.98M
Working Capital	$179.75M	$155.03M	$125.44M	$99.03M	$144.83M	$114.15M
Net Debt	—	—	—	—	$13.34M	$42.94M

INBX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$35.90M	-$29.95M	-$33.82M	-$30.12M	-$38.03M	-$29.92M
Capital Expenditure	-$21.00K	—	-$10.00K	—	—	—
Free Cash Flow	-$35.92M	-$29.95M	-$33.83M	-$30.12M	-$38.03M	-$29.92M
Depreciation & Amortisation	$675.00K	$661.00K	$583.00K	$564.00K	$537.00K	$523.00K
Stock-Based Compensation	$2.45M	$2.77M	$3.17M	$2.74M	$2.65M	$3.10M
Investing Cash Flow	-$21.00K	$0.00	-$7.00K	$0.00	$0.00	$0.00
Financing Cash Flow	$99.84M	$0.00	$352.00K	$1.25M	$75.46M	$1.60M
Net Change in Cash	$63.92M	-$29.95M	-$33.48M	-$28.87M	$37.44M	-$28.31M

Market Snapshot

About

Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology. The company's lead program targets alpha-fetoprotein (AFP)-positive tumors, including hepatocellular carcinoma, using a novel T cell engager platform. Inhibrx Biosciences leverages its proprietary single-domain antibody technology to create multi-specific therapeutics designed to redirect immune cells to tumor sites. The company's pipeline includes programs addressing difficult-to-treat solid tumors with high unmet medical needs.